Dr. Dunsire Brings Deep Biopharmaceutical Experience to Alexion's Board
NEW HAVEN, Conn.--(BUSINESS WIRE)--
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that Deborah
Dunsire, M.D. has been appointed to the Company's Board of Directors as
a new independent director. Dr. Dunsire is a proven leader in the
biopharmaceutical industry with three decades of experience and a
successful track record of growing businesses, fostering R&D and
commercial development, and creating shareholder value.
Dr. Dunsire served as President and Chief Executive Officer of
Millennium Pharmaceuticals, Inc. from 2005-2013, where she led the
transformation of the company into a biotechnology industry leader.
Prior to Millennium, which became Takeda Oncology, Dr. Dunsire led the
Novartis North America Oncology Business, which during her ten-year
tenure grew in revenues from $50 million to more than $2.2 billion, and
she served for eight years with Sandoz AG. Dr. Dunsire currently serves
as President and Chief Executive Officer of Xtuit Pharmaceuticals, Inc.,
a privately held biopharmaceutical company developing novel
therapeutics. Dr. Dunsire also serves on the boards of Xtuit and
Ultragenyx Pharmaceutical, Inc., and previously served on the boards of
Takeda Pharmaceuticals, Allergan, Inc. and FORUM Pharmaceuticals, Inc.
She received her medical degree from the University of Witwatersrand,
Johannesburg, South Africa.
David Brennan, Chairman of the Board, commented, "We are delighted to
welcome Deborah to Alexion's Board of Directors. Her experience will be
highly valuable to our board as we continue to position Alexion to
deliver long-term growth and sustainable value for our shareholders.
Alexion has made excellent progress over the past year, enhancing our
corporate governance, refocusing our business strategy and achieving
important corporate milestones. We look forward to working with Deborah
as we continue to build on our leadership in treating patients with rare
Dr. Dunsire added: "Alexion is a world-class organization with
innovative therapies and proven leadership in treating patients with
rare diseases. I am excited to join the Alexion Board and look forward
to contributing to the Company's continued success."
"Elliott strongly supports Deborah's appointment to the Alexion Board,"
said an Elliott spokesperson. "She is one of the biopharmaceutical
industry's most respected leaders and brings significant experience to
the Board. This is another welcome step by Alexion to build on its
recent accomplishments and enhance value creation for all shareholders."
Alexion is a global biopharmaceutical company focused on serving
patients and families affected by rare diseases through the innovation,
development and commercialization of life-changing therapies. Alexion is
the global leader in complement inhibition and has developed and
commercializes the first and only approved complement inhibitor to treat
patients with paroxysmal nocturnal hemoglobinuria (PNH), atypical
hemolytic uremic syndrome (aHUS), and anti-acetylcholine receptor (AchR)
antibody-positive generalized myasthenia gravis (gMG). In addition,
Alexion has two highly innovative enzyme replacement therapies for
patients with life-threatening and ultra-rare metabolic disorders,
hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D). As
the leader in complement biology for over 20 years, Alexion focuses its
research efforts on novel molecules and targets in the complement
cascade, and its development efforts on the core therapeutic areas of
hematology, nephrology, neurology, and metabolic disorders. This press
release and further information about Alexion can be found at: www.alexion.com.
This press release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended. These
forward-looking statements often include words such as "anticipate,"
"believe," "expect," "will," or similar expressions. Forward-looking
statements are subject to factors that may cause Alexion's results and
plans to differ from those expected, including the risks set forth from
time to time in Alexion's filings with the U.S. Securities and Exchange
Commission, including but not limited to the risks discussed in
Alexion's Quarterly Report on Form 10-Q for the period ended September
30, 2017 and in our other filings with the U.S. Securities and Exchange
Commission. Alexion does not intend to update any of these
forward-looking statements to reflect events or circumstances after the
date hereof, except when a duty arises under law.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180122006487/en/
Alexion Pharmaceuticals, Inc.
Kim Diamond, 475-230-3775
Director, Corporate Communications
Ridloff, CFA, 475-230-3601
Vice President, Investor Relations
Director, Investor Relations
Source: Alexion Pharmaceuticals, Inc.
News Provided by Acquire Media